Table 2.

Details of the endovascular treatment and clinical outcomes

	Non-tirofiban group (n = 59)	Tirofiban group (n = 59)	P value
Onset-to-puncture time	275 (210–482)	395 (274–580)	0.036
Puncture-to-final angiography time	81 (60–101)	65 (42–108)	0.064
Onset-to-reperfusion time	380 (298–646)	467 (345–675)	0.066
First-line endovascular treatment			0.096
Aspiration thrombectomy	29 (49.2%)	33 (55.9%)
Stent retriever	23 (39.0%)	25 (42.4%)
Local fibrinolytics	1 (1.7%)	1 (1.7%)
Angioplasty	6 (10.2%)	0
Immediate reocclusion after first endovascular method	10 (17.9%)	24 (41.4%)	0.006
Degree of residual stenosis prior to rescue treatment (%)	80 (71–86)	83 (79–90)	0.056
Rescue treatments
Local tirofiban infusion only	0	48 (81.4%)	< 0.001
Stent retriever to aspiration	1 (1.7%)	0	> 0.999a
Aspiration to stent retriever	8 (13.6%)	3 (5.1%)	0.113
Intracranial balloon angioplasty	9 (15.3%)	2 (3.4%)	0.027
Intracranial stenting	12 (20.3%)	6 (10.2%)	0.124
Final AOL 2–3	41 (69.5%)	41 (69.5%)	> 0.999
Final mTICI 2b–3	25 (42.4%)	51 (86.4%)	0.016
Postprocedural reocclusion	12 (37.5%, n = 32)	2 (4.4%, n = 45)	< 0.001
Intracerebral hemorrhage			0.311
HT type 1	4 (6.8%)	2 (3.4%)
HT type 2	6 (10.2%)	3 (5.1%)
PH type 1	3 (5.1%)	1 (1.7%)
PH type 2	6 (10.2%)	3 (5.1%)
Subarachnoid hemorrhage	6 (10.2%)	0	0.027a
Intraventricular hemorrhage	8 (13.6%)	1 (1.7%)	0.032a
Serious hemorrhagic complicationb	9 (15.3%)	3 (5.1%)	0.068
Final infarct volume, ml (median, IQR)	38.8 (14.3–92.7)	18.5 (7.9–37.2)	0.023
mRS 0–2 at 3 months	19 (32.2%)	31 (52.5%)	0.025
Mortality	12 (20.3%)	4 (6.8%)	0.031

AOL arterial occlusive lesion, ERT endovascular revascularization therapy, HT hemorrhagic transformation, mRS modified Rankin Scale, MT mechanical thrombectomy, mTICI modified treatment in cerebral ischemia, PH parenchymal hematoma

^aFisher’s exact t-test; ^bSerious hemorrhagic complications consist of parenchymal hematoma type 2 and/or subarachnoid hemorrhage Fisher grade 3–4